» Articles » PMID: 19898503

Effect of Missing Killer-immunoglobulin-like Receptor Ligand in Recipients Undergoing HLA Full Matched, Non-T-depleted Sibling Donor Transplantation: a Single Institution Experience of 151 Asian Patients

Overview
Specialty General Surgery
Date 2009 Nov 10
PMID 19898503
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This retrospective analysis studied the impact of natural killer (NK) alloreactivity based on the missing ligand model, for a cohort of recipients undergoing haemopoietic stem cell transplant without T-cell depletion from HLA full-matched sibling donors. All patients received a uniform myeloablative conditioning regimen and prophylaxis for GVHD. A total of 151 patients were studied, including 62 patients with AML or myelodysplastic syndrome, 42 patients with ALL and 47 patients with CML. We found that 81% of patients had at least one missing KIR-ligand (KIR-L), and HLA-C1 allogroup homozygosity is present in 70% of patients. From multivariate analysis, we observed that the only consistently significant factor that was associated with superior survival was disease stage. Missing KIR-L, whether considering HLA-Bw and HLA-C alleles, without or with HLA-A ligands or narrowing to only HLA-C alleles alone to classify the number of missing KIR-L, did not have any impact on OS or relapse-free survival. This negative finding implies that as the KIR-L composition of recipient is not important in this matched non-T-depleted setting, further immunotherapeutic measures involving adoptive NK cell infusions have to be explored to exploit the benefit of NK alloreactivity for such transplants.

Citing Articles

Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Gao F, Ye Y, Gao Y, Huang H, Zhao Y Front Immunol. 2020; 11:2022.

PMID: 32983145 PMC: 7493622. DOI: 10.3389/fimmu.2020.02022.


Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Wang W, Erbe A, Gallenberger M, Kim K, Carmichael L, Hess D Cancer Immunol Immunother. 2016; 65(12):1523-1532.

PMID: 27695964 PMC: 5123674. DOI: 10.1007/s00262-016-1904-8.